

Emilio Esteban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3822669/publications.pdf>

Version: 2024-02-01

132
papers

9,763
citations

236925

25
h-index

38395

95
g-index

139
all docs

139
docs citations

139
times ranked

11734
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
2	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2010, 11, 521-529.	10.7	1,158
3	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	1.6	710
4	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 822-835.	10.7	390
5	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 300-308.	10.7	360
6	Randomized Phase III Trial of Temozolomide Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 760-767.	1.6	331
7	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	10.7	239
8	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. <i>Lancet Oncology</i> , The, 2011, 12, 1143-1150.	10.7	217
9	Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non-Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3448-3455.	1.6	129
10	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	10.7	119
11	Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. <i>Journal of Clinical Oncology</i> , 2010, 28, LBA4518-LBA4518.	1.6	104
12	Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial. <i>Annals of Oncology</i> , 1991, 2, 751-754.	1.2	86
13	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e86263.	2.5	76
14	First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study. <i>Annals of Oncology</i> , 2011, 22, 924-930.	1.2	74
15	Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. <i>Annals of Oncology</i> , 2013, 24, 2409-2414.	1.2	73
16	Tumor markers at the time of recurrence in patients with germ cell tumors. <i>Cancer</i> , 2000, 88, 162-168.	4.1	62
17	Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. <i>Annals of Oncology</i> , 2007, 18, 1359-1362.	1.2	54
18	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <i>Cancer Epidemiology</i> , 2015, 39, 291-297.	1.9	39

#	ARTICLE	IF	CITATIONS
19	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. <i>JCI Insight</i> , 2016, 1, e86051.	5.0	39
20	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. <i>British Journal of Cancer</i> , 2015, 112, 1190-1198.	6.4	35
21	Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 840, 44-49.	2.3	31
22	Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. <i>British Journal of Cancer</i> , 2013, 108, 2565-2572.	6.4	31
23	Prognostic Factors in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 262-270.	1.9	29
24	Prognostic factors for response to systemic treatments carried out in patients with advanced renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 369-369.	1.6	28
25	Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 251-259.	2.3	26
26	Pemetrexed in first-line treatment of non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 364-373.	7.7	26
27	Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1165-1173.	2.4	25
28	Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. <i>Investigational New Drugs</i> , 2008, 26, 67-74.	2.6	22
29	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	4.4	22
30	Fate of Shiga Toxin-Producing O157:H7 and Non-O157:H7 Escherichia coli Cells within Refrigerated, Frozen, or Frozen Then Thawed Ground Beef Patties Cooked on a Commercial Open-Flame Gas or a Clamshell Electric Grill. <i>Journal of Food Protection</i> , 2013, 76, 1500-1512.	1.7	21
31	Predictive factors for response to treatment in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 2443-2449.	2.6	20
32	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptorâ€‘Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e777-e784.	1.9	20
33	Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. <i>Annals of Oncology</i> , 1991, 2, 151-152.	1.2	19
34	Latex Agglutination Assays for Detection of Non-O157 Shiga Toxinâ€‘Producing Escherichia coli Serogroups O26, O45, O103, O111, O121, and O145â€‘. <i>Journal of Food Protection</i> , 2012, 75, 819-826.	1.7	19
35	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. <i>British Journal of Cancer</i> , 2013, 109, 121-130.	6.4	19
36	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 30410-30421.	1.8	19

#	ARTICLE	IF	CITATIONS
37	Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. <i>Cancer</i> , 2004, 101, 2261-2269.	4.1	18
38	The trans-activating C-type retroviruses share a distinct epitope(s) that induces antibodies in certain infected hosts. <i>Journal of General Virology</i> , 1991, 72, 2113-2119.	2.9	17
39	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. <i>Future Oncology</i> , 2015, 11, 267-277.	2.4	17
40	Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. <i>Anti-Cancer Drugs</i> , 2007, 18, 291-296.	1.4	16
41	Oral Vinorelbine. <i>Drugs</i> , 2007, 67, 657-667.	10.9	16
42	Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2002, 20, 73-82.	2.6	14
43	Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study. <i>Investigational New Drugs</i> , 2006, 24, 241-248.	2.6	14
44	PTEN expression and mutations in TSC1 , TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 1435-1444.	5.1	14
45	Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. <i>Investigational New Drugs</i> , 2003, 21, 459-463.	2.6	13
46	Recommendations for the optimal management of early and advanced urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 431-441.	7.7	12
47	Quality of life and supportive care for patients with metastatic renal cell carcinoma. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 33-39.	5.9	11
48	Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 141-150.	2.5	10
49	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1-13.	2.3	10
50	HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4635-4643.	2.0	10
51	Inefficiency of cisplatin plus 5-FU as second-or third line treatment in advanced breast cancer. <i>Annals of Oncology</i> , 1991, 2, 521.	1.2	9
52	High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma. <i>Cancer</i> , 2001, 92, 2508-2516.	4.1	8
53	Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 478-485.	2.5	8
54	Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting. <i>Advances in Therapy</i> , 2017, 34, 136-147.	2.9	8

#	ARTICLE	IF	CITATIONS
55	Irinotecan in the Treatment of Advanced Colorectal Cancer in Patients Pretreated With Fluorouracil-Based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 107-111.	1.3	7
56	Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study. <i>Lung Cancer</i> , 2007, 55, 173-180.	2.0	7
57	Professional burnout among Spanish medical oncologists. <i>Clinical and Translational Oncology</i> , 2009, 11, 86-90.	2.4	7
58	Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. <i>BMC Cancer</i> , 2016, 16, 135.	2.6	7
59	Binational study of pediatric blood lead levels along the United States/Mexico border. <i>International Journal of Hygiene and Environmental Health</i> , 2006, 209, 235-240.	4.3	6
60	Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. <i>Future Oncology</i> , 2015, 11, 1665-1674.	2.4	6
61	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 66.	4.0	6
62	Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. <i>Journal of Translational Medicine</i> , 2017, 15, 62.	4.4	6
63	Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. <i>Cancer Research</i> , 2018, 78, CT075-CT075.	0.9	6
64	A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2000, 62, 127-133.	2.5	5
65	Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2002, 20, 317-326.	2.6	5
66	Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. <i>Investigational New Drugs</i> , 2011, 29, 1459-1464.	2.6	5
67	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. <i>European Urology Oncology</i> , 2021, 4, 502-505.	5.4	5
68	Negative phase II study with carboplatin and 5-fluorouracil in advanced breast cancer. <i>European Journal of Cancer</i> , 1992, 28, 242.	2.8	4
69	6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 361.	2.2	4
70	B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. <i>Journal of Thoracic Oncology</i> , 2007, 2, S334-S335.	1.1	4
71	Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. <i>Clinical and Translational Oncology</i> , 2010, 12, 562-567.	2.4	4
72	Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2433-2439.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). <i>Investigational New Drugs</i> , 2014, 32, 377-381.	2.6	4
74	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCulating Endothelial cells) Study (SOGUG-CEC-2011-01). <i>European Urology Focus</i> , 2017, 3, 430-436.	3.1	4
75	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. <i>Advances in Therapy</i> , 2019, 36, 1497-1508.	2.9	4
76	Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 1993, 29, 1354.	2.8	3
77	Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 1206-1207.	2.8	3
78	Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy. <i>Clinical and Translational Oncology</i> , 2008, 10, 426-432.	2.4	3
79	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 1-10.	5.9	3
80	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 11-20.	5.9	3
81	88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY. <i>Lung Cancer</i> , 2011, 71, S44.	2.0	3
82	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. <i>Targeted Oncology</i> , 2016, 11, 129-141.	3.6	3
83	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017, 7, 41371.	3.3	3
84	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	2.4	3
85	Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 573-579.	2.4	3
86	Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 781-789.	2.3	3
87	Cabazitaxel in patients with advanced CRPC after docetaxel failure: Results of expanded program access (EAP) in Spain: Safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15149-e15149.	1.6	3
88	Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 257-265.	2.5	2
89	O-113 Cisplatin plus gemcitabine with or without vinorelbine as neo-adjuvant therapy for radically treatable stage III Non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España). <i>Lung Cancer</i> , 2005, 49, S40.	2.0	2
90	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. <i>British Journal of Cancer</i> , 2006, 94, 1797-1802.	6.4	2

#	ARTICLE	IF	CITATIONS
91	2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. European Journal of Cancer, 2015, 51, S489.	2.8	2
92	Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. European Urology Focus, 2017, 3, 280-286.	3.1	2
93	102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT). Lung Cancer, 2009, 64, S45.	2.0	1
94	Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urology, 2015, 15, 15.	1.4	1
95	Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2016, 27, vi285.	1.2	1
96	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway targeted therapy and one prior mTOR inhibitor therapy.. Journal of Clinical Oncology, 2014, 32, 473-473.	1.6	1
97	Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment ABIDO-SOGUC Trial.. Journal of Clinical Oncology, 2015, 33, e16022-e16022.	1.6	1
98	Dacarbazine in advanced squamous cell carcinoma of the head and neck. European Journal of Cancer & Clinical Oncology, 1991, 27, 215-216.	0.7	0
99	362 Aminoglutethimide + hidrocortisone (AMG + HC) vs. megestrol acetate (MEG) as second and third line treatment in advanced breast cancer (ABC): A phase III study. European Journal of Cancer, 1995, 31, S79.	2.8	0
100	Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination. Investigational New Drugs, 2005, 23, 597-601.	2.6	0
101	P-482 Activity of topotecan in patients with advanced non-small cell lung cancer pre-treated with platinum and taxanes: Results of the first analysis. Lung Cancer, 2005, 49, S243.	2.0	0
102	P-641 Concurrent 70 gy thoracic radiotherapy with weekly docetaxel or paclitaxel after induction chemotherapy in patients with locally advanced non-small-cell lung cancer: Tolerance and efficacy from a non-randomized study. Lung Cancer, 2005, 49, S287.	2.0	0
103	Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis. Cancer Immunology, Immunotherapy, 2009, 58, 235-245.	4.2	0
104	143P CISPLATINUM PLUS DOCETAXEL (CD) AS INDUCTION CHEMOTHERAPY PRIOR TO RADICAL LOCOREGIONAL (LR) TREATMENT FOR PATIENTS (PTS) WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS OF A PROSPECTIVE PHASE II STUDY. Lung Cancer, 2009, 64, S59.	2.0	0
105	8051 Final results of a phase I study of pegylated liposomal doxorubicin + gemcitabine in prolonged infusion in patients with recurrent ovarian cancer less than one year. European Journal of Cancer, Supplement, 2009, 7, 464.	2.2	0
106	7161 POSTER Prognostic Factors in Patients With Advanced Renal Cell Carcinoma. European Journal of Cancer, 2011, 47, S523.	2.8	0
107	8048 POSTER Dose Finding Study of Carboplatin in First Line Chemotherapy in Advanced Ovarian Cancer. European Journal of Cancer, 2011, 47, S541.	2.8	0
108	2538 Response to cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC) poorly responding to docetaxel. European Journal of Cancer, 2015, 51, S488.	2.8	0

#	ARTICLE	IF	CITATIONS
109	2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain. <i>European Journal of Cancer</i> , 2015, 51, S488-S489.	2.8	0
110	CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?. <i>Clinical and Translational Oncology</i> , 2017, 19, 105-110.	2.4	0
111	KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. <i>Annals of Oncology</i> , 2018, 29, ix164.	1.2	0
112	PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. <i>Journal of Thoracic Oncology</i> , 2018, 13, S155.	1.1	0
113	230P Experience with the implant of vascular access devices by medical oncologists in a non-surgical setting. <i>Journal of Thoracic Oncology</i> , 2018, 13, S137-S138.	1.1	0
114	Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases. <i>Journal of Clinical Oncology</i> , 2005, 23, 4756-4756.	1.6	0
115	Role of the p38 β MAPK in the prognosis and prediction of response to neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2010, 28, e21073-e21073.	1.6	0
116	Prognostic factors in patients with advanced renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 391-391.	1.6	0
117	Predictive factors for response to systemic treatments carried out in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15014-e15014.	1.6	0
118	Prognostic factors in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15011-e15011.	1.6	0
119	Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4559-4559.	1.6	0
120	Protein BIII-tubulin expression as a prognostic and/or predictive factor of response to docetaxel in patients with hormone-refractory prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 84-84.	1.6	0
121	Prospective assessment of circulating endothelial cells (CECs) as early markers of clear cell renal cell carcinoma (CCRCC) progression in first-line setting: The Circles study (SOGUG 2011-01).. <i>Journal of Clinical Oncology</i> , 2013, 31, 436-436.	1.6	0
122	Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 537-537.	1.6	0
123	Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 235-235.	1.6	0
124	Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16088-e16088.	1.6	0
125	Prospective assessment of circulating endothelial cells (CECs) as markers of activity of first-line treatment in advanced clear cell renal cell carcinoma (CCRCC): The CIRCLES study (SOGUG 2011-01).. <i>Journal of Clinical Oncology</i> , 2014, 32, e22019-e22019.	1.6	0
126	Comparison of stem cell signaling pathways in long-term responders (LR) versus primary refractory (PR) patients with metastatic clear-cell renal cell carcinoma (ccRCC) under sunitinib (SU) treatment (SULONG study).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4578-4578.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Randomized phase II study of abiraterone acetate maintenance in combination with docetaxel after disease progression to abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC): ABIDO SOGUG trial.. Journal of Clinical Oncology, 2014, 32, TPS5096-TPS5096.	1.6	0
128	Metabolic syndrome (MetS) incidence in renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology, 2015, 33, e15587-e15587.	1.6	0
129	Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2016, 34, 5058-5058.	1.6	0
130	Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2016, 34, e16129-e16129.	1.6	0
131	Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC.. Journal of Clinical Oncology, 2016, 34, e16080-e16080.	1.6	0
132	Predictors of radiologic progression free survival (rPFS) during abiraterone acetate (AA) treatment in a randomized phase II study of AA maintenance in combination with docetaxel (D) after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): ABIDO-SOGUG trial.. Journal of Clinical Oncology, 2017, 35, e16536-e16536.	1.6	0